What is an inhalant allergy

Ahmed E, Sansac C, Assou S, Gras D, Petit A, Vachier I, Chanez P, De Vos J, Bourdin A. (2018). “Lung development, regeneration and plasticity: From disease physiopathology to drug design using induced pluripotent stem cells. “ Pharmacol Ther. 2018 Mar;183:58-77. (IF= 9,40).

Battault S, Meziat C, Nascimento A, Braud L, Gayrard S, Legros C, De Nardi F, Drai J, Cazorla O, Thireau J, Meyer G, Reboul C. (2018). “Vascular endothelial function masks increased sympathetic vasopressor activity in rats with metabolic syndrome.

What is an inhalant allergy

Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H497-H507. (IF=4,05).

Bouallègue FB, Vauchot F, Bourdon A, Benkiran M, Boissin C, Charriot J, Bourdin A, Mariano-Goulart D. (2018). “RV function improvement following nitric oxide inhalation demonstrated by gated blood pool SPECT in a patient with primary pulmonary hypertension.“ J Nucl Cardiol. 2018 Dec;25(6):2174-2176. (IF=4,11).

Bourdin A, Suehs CM, Marin G, Vachier I, Matzner-Lober E, Chanez P, Molinari N; COBRA consortium  (2018).

“Asthma, COPD and overlap in a national cohort: ACO on a gradient. “J Allergy Clin Immunol. 2018 Apr;141(4):1516-1518. (IF=14,11).

Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X. (2018). “Matching-Adjusted Indirect Comparison of Benralizumab versus Interleukin-5 Inhibitors: Systematic Review. “Eur Respir J. 2018 Nov 29;52(5).. (IF= 11,81).

Bulsei J, Leroy S, Perotin JM, Mal H, Marquette CH, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dukic S, Barbe C, Bonnaire M, Deslee G, Durand-Zaleski I; REVOLENS study group.

(2018). “Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study). “ Respir Res. 2018 May 9;19(1):84. (IF=3,83).

Canaud L, Gandet T, Ozdemir BA, Chassin-Trubert L, Alric P. (2018). “Custom Fenestration Templates for Endovascular Repair of the Aortic Arch. “ JEndovasc Ther. 2018 Oct;25(5):559-560. (IF=2,99).

Champéroux P, Fesler P, Judé S, Richard S, Le Guennec JY, Thireau J.

(2018). “High Frequency Autonomic Modulation: a new model for analysis of autonomic cardiac control. “ Br J Pharmacol. 2018 Aug;175(15):3131-3143. (IF=6,58).

Choquet C, Nguyen THM, Sicard P, Buttigieg E, Tran TT, Kober F, Varlet I, Sturny R, Costa MW, Harvey RP, Nguyen C, Rihet P, Richard S, Bernard M, Kelly RG, Lalevée N, Miquerol L. (2018). “Deletion of Nkx2-5 in trabecular myocardium reveals the developmental origins of pathological heterogeneity associated with ventricular non-compaction cardiomyopathy.

PLoS Genet. 2018 Jul 6;14(7):e1007502. / PLoS Genet. 2018 Aug 15;14(8):e1007610.( (IF=5,22).

Curinier C, Solecki K, Dupuy AM, Breuker C, Lotierzo M, Zerkowski L, Kalmanovich E, Akodad M, Adda J, Battistella P, Castet-Nicolas A, Kuster N, Marques S, Soltani S, Chettouh M, Verchere A, Belloc C, Roubille C, Fesler P, Mercier G, Cristol JP, Audurier Y, Roubille F.

(2018). “Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial. “ Contemp Clin Trials. 2018 Jan 30;66:45-50. (IF= 2,28).

Daïen CI, Tubery A, Cailar GD, Mura T, Roubille F, Morel J, Bousquet J, Fesler P, Combe B. (2018). “Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: data from an observational study.

Ann Rheum Dis. 2018 Apr;77(4):625-626 (IF=14,30).

Eliet J, Gaudard P, Zeroual N, Rouvière P, Albat B, Mourad M, Colson PH. (2018). “Effect of Impella During Veno-Arterial Extracorporeal Membrane Oxygenation on Pulmonary Artery Flow as Assessed by End-Tidal Carbon Dioxide. “ ASAIO J. 2018 Jul/Aug;64(4):502-507  (IF=2,49).

Engi A, Sansac C, Fieldes M, Bergougnoux A, Bourguignon C, Mianne J, Arnould C, Vachier I, Assou S, Bourdin A, De Vos J.

(2018). Generation of the induced pluripotent stem cell line UHOMi001-A from a patient with mutations in CCDC40 gene causing Primary Ciliary Dyskinesia (PCD)STEM CELL Research. 2018  Volume 33, December 2018, Pages 15-19 . (IF=3,93).

Eyries M, Montani D, Nadaud S, Girerd B, Levy M, Bourdin A, Trésorier R, Chaouat A, Cottin V, Sanfiorenzo C, Prevot G, Reynaud-Gaubert M, Dromer C, Houeijeh A, Nguyen K, Coulet F, Bonnet D, Humbert M, Soubrier F.(2018).”Widening the landscape of heritable pulmonary hypertension mutations in pediatric and adult cases.”Eur Respir J. 2018 Dec 21.

Sous presse. (IF=11,81)

Faure EM, El Batti S, Abou Rjeili M, Julia P, Alsac JM. (2018). “Mid-term Outcomes of Stent Assisted Balloon Induced Intimal Disruption and Relamination in Aortic Dissection Repair (STABILISE) in Acute Type B Aortic Dissection. “ Eur J Vasc Endovasc Surg. 2018 Aug;56(2):209-215.

What is an inhalant allergy

(IF=3,64).

Faure EM, El Batti S, Abou Rjeili M, Ben Abdallah I, Julia P, Alsac JM. (2018). “Stent-assisted, balloon-induced intimal disruption and relamination of aortic dissection in patients with Marfan syndrome: Midterm outcomes and aortic remodeling. “  J Thorac Cardiovasc Surg. 2018 Nov;156(5):1787-1793 (IF=5,26).

Galano JM, Roy J, Durand T, Lee JC, Le Guennec JY, Oger C, Demion M.

What is an inhalant allergy

(2018). Biological activities of non-enzymatic oxygenated metabolites of polyunsaturated fatty acids (NEO-PUFAs) derived from EPA and DHA: New anti-arrhythmic compounds?Mol Aspects Med. 2018 Dec;64:161-168. doi: (IF=8,31).

Gaudard P, Barbanti C, Rozec B, Mauriat P, M’rini M, Cambonie G, Liet JM, Girard C, Leger PL, Assaf Z, Damas P, Loron G, Lecourt L, Amour J, Pouard P.

(2018). New Modalities for the istration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study.Anesth Analg. 2018 Apr;126(4):1234-1240 (IF=3,49).

Gerges C, Gerges M, Fesler P, Maria Pistritto A, Konowitz NP, Jakowitwsch J, Celermajer DS, Lang IM. (2018). “In-depth hemodynamic phenotyping of pulmonary hypertension due to left heart disease. “ Eur Respir J. 2018 May 24;51(5).(IF=11,81).

Granier M, Laugaudin G, Massin F, Cade S, Winum PF, Freitag C, Pasquie JL.

(2018). “Occurrence of Incomplete Endothelialization Causing Residual Permeability After Left Atrial Appendage Closure. “ J Invasive Cardiol. 2018 Jul;30(7):245-250 (IF=1,36).

Haïssaguerre M, Hocini M, Cheniti G, Duchateau J, Sacher F, Puyo S, Cochet H, Takigawa M, Denis A, Martin R, Derval N, Bordachar P, Ritter P, Ploux S, Pambrun T, Klotz N, Massoullié G, Pillois X, Dallet C, Schott JJ, Scouarnec S, Ackerman MJ, Tester D, Piot O, Pasquié JL, Leclerc C, Hermida JS, Gandjbakhch E, Maury P, Labrousse L, Coronel R, Jais P, Benoist D, Vigmond E, Potse M, Walton R, Nademanee K, Bernus O, Dubois R.

(2018) “Localized Structural Alterations Underlying a Subset of Unexplained Sudden Cardiac Death. “ Circ Arrhythm Electrophysiol. 2018 Jul;11(7):e006120. (IF=4,97).

Halimi L, Marin G, Molinari N, Gamez AS, Boissin C, Suehs CM, Vachier I, Bourdin A. (2018). “Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension. “ J Psychosom Res. 2018 Feb;105:45-51. (IF=2,72).

Jaffuel D, Molinari N, Berdague P, Pathak A, Galinier M, Dupuis M, Ricci JE, Mallet JP, Bourdin A, Roubille F.

(2018). « Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.ESC Heart Fail. 2018 Jun;5(3):222-230. (IF=3,41).

Kolia-Diafouka P, Godreuil S, Bourdin A , Carrère-Kremer S, Kremer L,  Van De Perre P and  Tuaillon E (2018)  “Optimized Lysis-Extraction Method Combined with IS6110-Amplification for Detection of Mycobacterium tuberculosis in Paucibacillary Specimens  “. Front.

Microbiol. 18 Sep 25;9:2224. (IF=4,26).

Lambert K, Hokayem M, Thomas C, Fabre O, Cassan C, Bourret A, Bernex F, Lees J, Demion M, Seyer P, Hugon G, Mercier J, Avignon A, Bisbal C. (2018). “No Additive Effects of Polyphenol Supplementation and Exercise Training on White Adiposity Determinants of High-Fat Diet-Induced Obese Insulin-Resistant Rats. “Oxid Med Cell Longev. 2018 Apr sous presse; (IF=4,87).

Léopold V, Gayat E, Pirracchio R, Spinar J, Parenica J, Tarvasmäki T, Lassus J, Harjola VP, Champion S, Zannad F, Valente S, Urban P, Chua HR, Bellomo R, Popovic B, Ouweneel DM, Henriques JPS, Simonis G, Lévy B, Kimmoun A, Gaudard P, Basir MB, Markota A, Adler C, Reuter H, Mebazaa A, Chouihed T.

(2018). “Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. “ Intensive Care Med. 2018 Jun;44(6):847-856. (IF=18,97).

Martinez-Anton A, Gras D, Bourdin A, Dubreuil P, Chanez P. (2018).KIT as a therapeutic target for non-oncological diseases.Pharmacol Ther. 2018 Dec 14. Sous presse. (IF=9,40).

Mianné J, Ahmed E, Bourguignon C, Fieldes M, Vachier I, Bourdin A, Assou S, De Vos J.

(2018). “Induced Pluripotent Stem Cells for Primary Ciliary Dyskinesia Modeling and Personalized Medicine. “Am J Respir Cell Mol Biol. 2018 Dec;59(6):672-683 (IF=3,34).

Montani D, Henry J, O’Connell C, Jaïs X, Cottin V, Launay D, Habib G, Bourdin A, Jevnikar M, Savale L, Rottat L, Simonneau G, Sitbon O, Humbert M, Allanore Y. (2018). “Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry.

Respiration. 2018;95(4):244-250.IF=2,93).

Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C. (2018). Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.Cancer Lett. 2018 Jun 20;432:227-236.

(IF=6,51).

Perotin JM, Leroy S, Marquette CH, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Barbe C, Deslee G; REVOLENS Study Group. (2018). “Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency. “ Int J Chron Obstruct Pulmon Dis. 2018 Nov 5;13:3645-3649. (IF=2,27).

Plawecki M, Morena M, Kuster N, Chenine L, Leray-Moragues H, Jover B, Fesler P, Lotierzo M, Dupuy AM, Klouche K, Cristol JP.

(2018). “sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction. “ Mediators Inflamm. 2018 Oct 8;2018:3952526. (IF=3,54).

Rénier W, Bourdin A, Rubbo PA, Peries M, Dedieu L, Bendriss S, Kremer L, Canaan S, Terru D, Godreuil S, Nagot N, Van de Perre P, Tuaillon E. (2018). “B cells response directed against Cut4 and CFP21 lipolytic enzymes in athletic and latent tuberculosis infections.

What is an inhalant allergy

PLoS One. 2018 Apr 30;13(4):e0196470. (IF=2,78).

Romano-Bertrand S, Evrevin M, Dupont C, Frapier JM, Sinquet JC, Bousquet E, Albat B, Jumas-Bilak E (2018). “Persistent Contamination of Heater-Cooler Units for Extracorporal Circulation Cured by Chlorhexidine-Alcohol in Water Tanks. “ J Hosp Infect. 2018 Jul;99(3):290-294. (IF = 3,70).

Rouhana S, Farah C, Roy J, Finan A, Rodrigues de Araujo G,Bideaux P,Scheuermann V, Saliba Y, Reboul C, Cazorla O, Aimond F, Richard S,Thireau J, Fares N.

(2018). “  Early calcium handling imbalance in pressure overload-induced heart failure with almost normal left ventricular ejection part  “  BBA Molecular Basis of Disease 2018 sous presse. (IF=4,33).

Teiger E, Thambo JB, Defaye P, Hermida JS, Abbey S, Klug D, Juliard JM, Pasquie JL, Rioufol G, Lepillier A, Elbaz M, Horvilleur J, Brenot P, Pierre B, Le Corvoisier P; French National Left Atrial Appendage Closure Registry (FLAAC) Investigators. (2018). “Percutaneous Left Atrial Appendage Closure Is a Reasonable Option for Patients With Atrial Fibrillation at High Risk for Cerebrovascular Events.

» Circ Cardiovasc Interv. 2018 Mar;11(3):e005841.(IF=6,06).

Zeroual N, Samarani G, Gallais J, Culas G, Saour M, Mourad M, Gaudard P, Colson PH. (2018). “ScvO2 changes after red-blood-cell transfusion for anaemia in cardiothoracic and vascular ICU patients: an observational study. “ Vox Sang. 2018 Feb;113(2):136-142 (IF=2,36).


Année 2017

Bardin PG, Price D, Chanez P, Humbert M, Bourdin A.

(2017). “Managing asthma in the era of biological therapies. “ Lancet Respir Med. 2017 May;5(5):376-378. (IF=21,47).

Bergougnoux A, Petit A, Knabe L, Bribes E, Chiron R, De Sario A, Claustres M, Molinari N, Vachier I, Taulan-Cadars M, Bourdin A. (2017). “The HDAC inhibitor SAHA does not save CFTR membrane expression in Cystic Fibrosis.“. The International Journal of Biochemistry & CellBiology 2017 Jul;88:124-132.. (IF=3,25).

Bommart S, Marin G, Molinari N, Knabe L, Petit A, Chanez P, Gamez AS, Devautour C, Vachier I, Bourdin A.

(2017). “CCSP Serum Level is A Surrogate Marker of Little Airway Involvment in Asthma. “. J Allergy Clin Immunol. 2017 Aug;140(2):581-584. (IF=13,26).

Bonnet B, Jourdan F, du Cailar G, Fesler P. (2017). “Non invasive evaluation of left ventricular elastance according to pressure-volume curves modeling in arterial hypertension. “Am J Physiol Heart Circ Physiol. 2017 Aug 1;313(2):H237-H243.

(IF=3,57) .

Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O. (2017). “Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.“ Eur Respir J. 2017 Aug 3;50(2). (IF=12,24).

Bourdin A, Molinari N. (2017). “[What are the socio-economic consequences of acute COPD exacerbations?] “ “ Rev Mal Respir.2017 Apr;34(4):338-342 (IF=0,58).

Bourdin A, Molinari N, Vachier I, Pahus L, Suehs C, Chanez P. (2017). “Mortality: a neglected outcome in OCS-treated severe asthma. “ Eur Respir J. 2017 Nov 30;50(5). (IF= 12,24).

Branquinho RT, Roy J, Farah C, Garcia GM, Aimond F, Le Guennec JY, Saude-Guimarães DA, Grabe-Guimaraes A, Mosqueira VC, de Lana M, Richard S. (2017). “ Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti-Trypanosomal Lychnopholide. “ Sci Rep. 2017 Mar 28;7:44998. (IF=4,12).

Bussiere R, Lacampagne A, Reiken S, Liu X, Scheuerman V, Zalk R, Martin C, Checler F, MarksAR , and Chami M.

(2017) “Amyloid β production is regulated by β2-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor. “Journal of Biological Chemistry Jun 16;292(24):10153-10168. (IF= 4,01).

Cabon Y, Molinari N, Marin G, Vachier I, Gamez AS, Chanez P and Bourdin A. (2017). “Comparison of anti-interleukin-5 therapies in patients with severe asthma: Global and indirect meta-analyses of randomized placebo-controlled trials“Clin Exp Allergy.

2017 Jan;47(1):129-138.. (IF=5,16).

Cadelis G, Ducrot R, Bourdin A, Rastogi N. (2017). “Predictive factors for a one-year improvement in nontuberculous mycobacterial pulmonary disease: An 11-year retrospective and multicenter study. “ PLoS Negl Trop Dis. 2017 Aug 7;11(8):e0005841. (IF=4,37).

Colomb S, Bareil C, Baccino E, Berthet JP, Knabe L, Vachier I, Bourdin A.(2017). “LIFE BEYOND LIFE – An Simple Way to Derive Lung Fibroblasts from Cadavers. “ J Forensic Sci. 2017 Sep;62(5):1339-1344 (IF=1,18).

Demion M, Oger C , Vigor C,  Thireau J, Le Guennec JY, Durand T, Galano JM, Chung-Yung Lee J.

(2017).”Two sides of the same coin: NEO‐PUFAs in Rett syndrome and post‐infarction cardiac arrhythmias.”European Journal of Lipid Science and Technology. 2017 119 (6). 1600320 (1 of 7) (IF=2,20).

Deslée G, Leroy S, Perotin JM, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dury S, Benzaquen J, Bonnaire M, Dukic S, Barbe C, Marquette CH; , on behalf of the REVOLENS Study Group13; REVOLENS Study Group. (2017). “Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study.

Eur Respir J. 2017 Dec 21;50(6). (IF=12,24).

Faure EM, Khantalin I, Peyron PA, Canaud L, Marty-Ané C, Alric P. (2017). “Experimental Assessment of Physician Modified Proximal Scalloped Stent Graft to Extend Proximal Landing Zone in the Aortic Arch. “  Eur J Vasc Endovasc Surg. 2017 Aug;54(2):150-156.

(IF=3,88).

Gueffier M, Zintz J, Lambert K, Finan A,Aimond F, Chakouri N, Hédon C, Granier M, Launay P, Thireau J, Richard S, Demion M. (2017). “ The TRPM4 channel is functionally significant for the beneficial cardiac remodeling induced by endurance training. “  J Muscle Res Cell Motil. 2017 Feb;38(1):3-16. (IF=2,10).

Gras D, Martinez-Anton A, Bourdin A, Garulli C, de Senneville L, Vachier I, Vitte J, Chanez P.(2017).Human bronchial epithelium orchestrates dendritic cell activation in severe asthma.Eur Respir J. 2017 Mar 8;49(3).(IF=12,24).

Gras D, Petit A, Charriot J, Knabe L, Alagha K, Gamez AS, Garulli C, Bourdin A, Chanez P, Molinari N, Vachier I.

(2017). “ Epithelial ciliated beating cells essential for ex vivo ALI culture growth. “   BMC Pulm Med. 2017 May 3;17(1):80. (IF=2,72).

Hautefort A, Chesné J, Preussner J, Pullamsetti SS, Tost J, Looso M, Antigny F, Girerd B, Riou M, Eddahibi S, Deleuze JF, Seeger W, Fadel E, Simonneau G, Montani D, Humbert M and Perros F. (2017). “Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. “Oncotarget 2017 May 19;8(32):52995-53016. (IF=5,17).

Jaffuel D, Mallet JP, Dauvilliers Y, Bourdin A.

(2017). “Is the Muscle the Only Potential Target of Desipramine in Obstructive Sleep Apnea Syndrome? “Am J Respir Crit Care Med. 2017 Jun 15;195(12):1677-1678.. (IF=15,24).

Jouneau S, Dres M, Guerder A, Bele N, Bellocq A, Bernady A, Berne G, Bourdin A, Brinchault G, Burgel PR, Carlier N, Chabot F, Chavaillon JM, Cittee J, Claessens YE, Delclaux B, Deslée G, Ferré A, Gacouin A, Girault C, Ghasarossian C, Gouilly P, Gut-Gobert C, Gonzalez-Bermejo J, Jebrak G, Le Guillou F, Léveiller G, Lorenzo A, Mal H, Molinari N, Morel H, Morel V, Noel F, Pégliasco H, Perotin JM, Piquet J, Pontier S, Rabbat A, Revest M, Reychler G, Stelianides S, Surpas P, Tattevin P, Roche N.

(2017). “Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary). “Rev Mal Respir. 2017 Apr;34(4):282-322. (IF=0,58).

Khoueiry Z, Providencia R, Combes S, Combes N, Pasquie JL, Albenque JP, Boveda S. (2016). “Cryoablation of paroxysmal atrial fibrillation displayed the same results as radiofrequency despite anatomical variants of pulmonary veins. “ Europace. Oct 1;19(10):1754-1755 (IF= 5,23).

Le Guennec JY, Thireau J, Ouillé A, Roussel J, Roy J, Richard S, Richard S, Martel E, Champéroux P.

(2017). “Corrigendum: Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety? “Sci Rep. 2017 Feb 16;7:42828. (IF=4,12)

Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padovani B, Israel-Biet D, Pison C, Chanez P, Cadranel J, Mazières J, Jounieaux V, Cohen C, Hofman V, Ilie M, Hofman P, Marquette CH; AIR Project Study Group collaboration A. Bourdin .(2017). “Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France.

BMJ Open. 2017 Dec 26;7(12):e018884. (IF=2,41).

Mercier O, Ataam JA,. Langer NB, r Dorfmüller P, Lamrani L, Lecerf  F, Decante B, Dartevelle P, Eddahibi S, Fadel E. (2017). “Abnormal pulmonary endothelial cells may underlie the enigmatic pathogenesis of chronic thromboembolic pulmonary hypertension..“.The Journal of Heart and Lung Transplantation. 2017 Mar;36(3):305-314. (IF=7,95).

Morra S, Bughin F, Solecki K, Aboubadra M, Lattuca B, Gouzi F, Macia JC, Cung TT, Cade S, Cransac F, Davy JM, Dauvilliers Y, Corrado D, Roubille F.

(2017). “Prevalence of obstructive sleep apnoea in acute coronary syndrome: Routine screening in intensive coronary care units. “Ann Cardiol Angeiol (Paris). 2017 Sep;66(4):223-229. (IF=0,27).

Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators.. (2017). “Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. “ N Engl J Med. 2017 Jun 22;376(25):2448-2458 (IF=79,26).

Plawecki M, Morena M, Kuster N, Chenine L, Leray-Moragues H, Jover B, Fesler P, Lotierzo M, Dupuy AM, Klouche K, Cristol JP.

(2018). “sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction. “ Mediators Inflamm. 2018 Oct 8;2018:3952526. (IF=3,50).

Reboul C, Boissière J, André L, Meyer G, Bideaux P, Fouret G, Feillet-Coudray C, Obert P, Lacampagne A, Thireau J, Cazorla O, Richard S. (2017). Carbon monoxide pollution aggravates ischemic heart failure through oxidative stress pathway.Sci Rep. 2017 Jan 3;7:39715 (IF=4,12).

Rotty MC, Mallet JP, Borel JC, Suehs CM, Bourdin A, Molinari N, Jaffuel D.

(2017). “The feasibility of a mandibular movement test as a screening tool for polysomnography candidates. “ Eur Respir J. 2017 Nov 30;50(5). (IF= 12,24).

Roy J, Le Guennec JY. (2016). “Cardioprotective effects of omega 3 fatty acids: origin of the variability. “ J Muscle Res Cell Motil. 2017 Feb;38(1):25-30 (IF=2,10).

Roy J, Fauconnier J, Oger C, Farah C, Angebault-Prouteau C, Thireau J,Bideaux P,Scheuermann V, Bultel-Poncé V, Demion M, Galano JM, Durand T, Lee JC, Le Guennec JY. (2017).

“Non-enzymatic oxidized metabolite of DHA, 4(RS)-4-F4t-neuroprostane protects the heart against reperfusion injury. “ Free Radic Biol Med. 2017 Jan;102:229-239.

What is an inhalant allergy

(IF=6,02).

Roy J, Galano JM, Durand T, Le Guennec JY, Lee JC.(2017). “Physiological role of reactive oxygen species as promoters of natural defenses. “ FASEB J. 2017 2017 Sep;31(9):3729-3745 (IF=5,59).

Sankhe S, Manousakidi S, Antigny F, Ataam JA, Bentebbal S, Ruchon Y, Lecerf F, Sabourin J, Price L, Fadel E, Dorfmüller P, Eddahibi S, Humbert M, Perros F, Capuano V. (2017). “T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.BBA – Molecular Cell Research 2017 Oct;1864(10):1631-1641.(IF=4,65).

Souza ACM, Mosqueira VCF, Silveira APA, Antunes LR, Richard S, Guimarães HN, Grabe-Guimarães A.

(2017). “Reduced cardiotoxicity and increased oral efficacy of artemether polymeric nanocapsules in Plasmodium berghei-infected mice. “ Parasitology. 2017 Dec 10:1-9. (IF= 2,51).

Thireau J,Farah C, Molinari N, Bouilloux F, Torreilles L, Winkelmann J, Scholz S, Richard S, Dauvilliers Y, Marmigère F. (2017). “MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome. “ Sci Rep. 2017 Apr 20;7:46620.

(IF=4,12).

Yang Z, Kirton H, Al-Owais M, Thireau J, Richard S, Steele D, Peers C. (2017). “Epac2-Rap1 signaling regulates reactive oxygen species production and susceptibility to cardiac arrhythmias. » Antioxid Redox Signal. 2017 Jul 20;27(3):117-132. (IF=6,53).


Method NameA short description of the method used to act out the test

Fluorescence Enzyme Immunoassay (FEIA)


Reporting NameLists a shorter or abbreviated version of the Published Name for a test

Resp Profile, Reg 4, Subtropic FLA

AliasesLists additional common names for a test, as an aid in searching

Refer to individual tests for lists of aliases

Test ID Reporting Name Available Separately Always Performed
IGE Immunoglobulin E (IgE), S Yes Yes
DP House Dust Mites/D.P., IgE Yes Yes
DF House Dust Mites/D.F., IgE Yes Yes
CAT Cat Epithelium, IgE Yes Yes
DOGD Dog Dander, IgE Yes Yes
BERG Bermuda Grass, IgE Yes Yes
TIMG Timothy Grass, IgE Yes Yes
BAHG Bahia Grass, IgE Yes Yes
COCR Cockroach, IgE Yes Yes
PENL Penicillium, IgE Yes Yes
CLAD Cladosporium, IgE Yes Yes
ASP Aspergillus Fumigatus, IgE Yes Yes
ALTN Alternaria Tenuis, IgE Yes Yes
BXMPL Box Eld/Maple, S, IgE Yes Yes
CED Mountain Cedar, IgE Yes Yes
OAK Oak, IgE Yes Yes
ELM Elm, IgE Yes Yes
APIN Australian Pine, IgE Yes Yes
SRW Short Ragweed, IgE Yes Yes
RRRP Rough Pigweed, IgE Yes Yes
SORR Red Sorrel, IgE Yes Yes
NETT Nettle, IgE Yes Yes
BTROP Blomia Tropicalis, IgE Yes Yes

Assessing sensitization to various inhalant allergens commonly found in sub-tropic Florida, which is south of Orlando

Immunoglobulin E (IgE) is one of the 5 classes of immunoglobulins, and is defined by the presence of the epsilon heavy chain.

It is the most recently described immunoglobulin, having first been identified in 1966. IgE exists as a monomer, and is present in circulation at extremely low concentrations, approximately 300-fold lower than that of IgG. The physiologic role of IgE is not well characterized, although it is thought to be involved in defense against parasites, specifically helminthes.

The function of IgE is also distinct from other immunoglobulins in that it induces activation of mast cells and basophils through the cell-surface receptor Fc epsilon RI. Fc epsilon RI is a high-affinity receptor specific for IgE present at a high density on tissue-resident mast cells and basophils.

Because of this high-affinity interaction, almost every IgE produced by B cells is bound to mast cells or basophils, which explains the low concentration present in circulation. Cross-linking of the Fc epsilon RI -bound IgE leads to cellular activation, resulting in immediate release of preformed granular components (histamine and tryptase) and subsequent production of lipid mediators (prostaglandins and leukotrienes) and cytokines (interleukin-4 and interleukin-5).

Elevated concentrations of IgE may happen in the context of allergic disease. However, increases in the quantity of circulating IgE can also be found in various other diseases, including primary immunodeficiencies, infections, inflammatory diseases, and malignancies.

Entire IgE measurements own limited utility for diagnostic evaluation of patients with suspected allergic disease. In this scenario, testing for the presence of allergen-specific IgEs may provide more information.

Clinical manifestations of allergic disease result from activation of mast cells and basophils, which occurs when Fc epsilon RI -bound IgE antibodies interact with allergen.

In vitro serum testing for specific IgE antibodies may provide an indication of the immune response to an allergen that may be associated with allergic disease.

The allergens chosen for testing often depend upon the age of the patient, history of allergen exposure, season of the year, and clinical manifestations.

Sensitization to inhalant allergens (dust mite, mold, and pollen inhalants) primarily occurs in older children, adolescents, and adults, and generally manifests as respiratory disease (rhinitis and asthma).

Specific IgE:

Class

IgE kU/L

Interpretation

0

<0.35

Negative

1

0.35-0.69

Equivocal

2

0.70-3.49

Positive

3

3.50-17.4

Positive

4

17.5-49.9

Strongly positive

5

50.0-99.9

Strongly positive

6

> or =100

Strongly positive

Reference values apply to every ages.

Total IgE:

Results Reported in kU/L

Age

Reference interval

0-5 months

< or =13

6-11 months

< or =34

1 and 2 years

< or =97

3 years

< or =199

4-6 years

< or =307

7 and 8 years

< or =403

9-12 years

< or =696

13-15 years

< or =629

16 and 17 years

< or =537

18 years and older

< or =214

Elevated concentrations of entire IgE may be found in a variety of clinical diseases, including allergic disease, certain primary immunodeficiencies, infections, inflammatory diseases, and malignancies.

Detection of allergen-specific IgE antibodies in serum (Class 1 or greater) indicates an increased likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be responsible for eliciting signs and symptoms.

An elevated concentration of entire IgE is not diagnostic for allergic disease, and must be interpreted in the clinical context of the patient, including age, gender, travel history, potential allergen exposure, and family history.

A normal concentration of entire IgE does not eliminate the possibility of allergic disease.

In patients with a high index of suspicion for allergic disease, testing for allergen-specific IgEs may be warranted.

Testing for allergen-specific IgE antibodies is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists, or in patients in whom the medical management does not depend upon identification of allergen specificity.

Some individuals with clinically insignificant sensitivity to allergens may own measurable levels of IgE antibodies in serum, and results must be interpreted in the clinical context.

False-positive results for IgE antibodies may happen in patients with markedly elevated serum IgE (>2,500 kU/L) due to nonspecific binding to allergen solid phases.

1.

Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by Laboratory Methods. 21st edition. New York, WB Saunders Company, 2007, pp 961-971

2. Bernstein IL, Li JT, Bernstein DI, et al: Allergy diagnostic testing: An updated practice parameter. Ann Allergy Asthma Immunol 2008 Mar;100(3 Suppl 3):S1-148

Simpson A, Brough HA, Haider S, Belgrave D, Murray CS, Custovic Aet al., 2019, Early-life inhalant allergen exposure, filaggrin genotype and the development of sensitization from infancy to adolescence, Journal of Allergy and Clinical Immunology, ISSN: 0091-6749

BackgroundWe hypothesized that filaggrin loss-of-function mutations modify the impact of allergen exposure on the development of allergic sensitization.ObjectiveTo determine whether early-life exposure to inhalant allergens increases the risk of specific sensitization, and whether filaggrin mutations modulate these odds.MethodsIn a population-based birth cohort, we measured mite, cat and dog allergen levels in dust samples collected from homes within the first year of life.

Sensitization was assessed at 6 time-points between infancy and age 16 years. Genotyping was performed for six filaggrin mutations.ResultsIn the longitudinal multivariable model (age 1-16 years), we observed a significant interaction between filaggrin and Fel d 1 exposure on cat sensitization, with the effect of exposure being significantly greater among children with filaggrin mutations compared to those without (OR 1.36, 95% CI 1.02-1.80, p=0.035). The increase in risk of mite sensitization with increasing Der p 1 exposure was consistently higher among children with filaggrin mutations, but the interaction did not reach statistical significance.

Diverse association were observed for dog: there was a significant interaction between filaggrin and dog ownership, but the risk of sensitization to any allergen was significantly lower among children with filaggrin mutations who were exposed to dog in infancy (OR 0.16, 95% CI 0.03–0.86, p=0.03).ConclusionsFilaggrin loss-of function mutations modify the relationship between allergen exposure and sensitization, but effects differ at diverse ages and between diverse allergens.

Nakamura T, Haider S, Murray CS, Fontanella S, Simpson A, Custovic Aet al., 2019, Impact of diverse definitions of atopic dermatitis on phenotyping the long-term course of the disease, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 29-29, ISSN: 0105-4538

Oksel C, Granell R, Haider S, Fontanella S, Simpson A, Turner S, Devereux G, Arshad SH, Murray CS, Roberts G, Holloway JW, Cullinan P, Henderson J, Custovic A, STELAR and Breathing Together investigatorset al., 2019, Distinguishing wheezing phenotypes from infancy to adolescence: a pooled analysis of five birth cohorts, Annals of the American Thoracic Society, Vol: 16, Pages: 868-876, ISSN: 2329-6933

RATIONALE: Pooling data from multiple cohorts and extending the time-frame across childhood should minimize study-specific effects, enabling better characterization of the childhood wheezing.

OBJECTIVE: To analyze wheezing patterns from early childhood to adolescence using combined data from five birth cohorts. METHODS: We used latent class analysis to derive wheeze phenotypes among 7719 participants from five birth cohorts with finish report of wheeze at five time-periods. We tested the association of derived phenotypes with tardy asthma outcomes and lung function, and investigated the uncertainty in phenotype assignment. RESULTS: We identified five phenotypes: Never/Infrequent wheeze (52.1%), Early-onset pre-school remitting (23.9%), Early-onset mid-childhood remitting (9%), Persistent (7.9%) and Late-onset wheeze (7.1%).

Compared to the Never/infrequent wheeze, every phenotypes had higher odds of asthma and lower FEV1 and FEV1/FVC in adolescence. The association with asthma was strongest for Persistent wheeze (adjusted odds ratio 56.54, 95%CI 43.75-73.06). We observed considerable within-class heterogeneity at individual level, with 913 (12%) children having low membership probability (<0.60) of any phenotype. Class membership certainty was highest in Persistent and Never/infrequent, and lowest in Late-onset wheeze (with 51% of participants having membership probabilities<0.80). Individual wheezing patterns were particularly heterogeneous in Late-onset wheeze, while numerous children assigned to Early-onset pre-school remitting class reported wheezing at later time points.

CONCLUSIONS: Every wheeze phenotypes had significantly diminished lung function in school-age, suggesting that the notion that early-life episodic wheeze has a benign prognosis may not be true for a proportion of transient wheezers. We observed considerable within-phenotype heterogeneity in individual wheezing patterns.

Haider S, Nakamura T, Colicino S, Murray C, Holloway J, Simpson A, Cullinan P, Custovic Aet al., 2019, Diverse definitions of atopic dermatitis: Impact on prevalence estimates and associated risk factors, British Journal of Dermatology, ISSN: 1365-2133

BackgroundThere is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD), and no uniform clinical definition.ObjectiveTo investigate to what extent operational definitions of AD cause fluctuation in the prevalence estimates and the associated risk factors.MethodsWe first reviewed operational definitions of AD used in the literature.

We then tested the impact of the choice of the most common definitions of “Cases” and “Controls” on AD prevalence estimates and associated risk factors (including filaggrin‐FLG mutations) among children aged 5 years in two population‐based birth cohorts: Manchester Asthma and Allergy Study (MAAS) and Asthma in Ashford. Model performance was measured by the percentage of children within an area of clinical indecision (defined as having a posterior probability of AD between 25% and 60%).ResultsWe identified 59 diverse definitions of AD across 45 reviewed studies.

Of those, we chose 4 common “Case” definitions, and 2 definitions of “Controls”. The prevalence estimates using diverse case definitions ranged between 22% and 33% in MAAS, and 12% and 22% in Ashford. The area of clinical indecision ranged from 32% to 44% in MAAS, and from 9% to 29% in Ashford. Depending on the case definition used, the associations with FLG mutations varied (ORs [95% CI]: 1.8 [1.1‐2.9] to 2.2 [1.3‐3.7] (MAAS) and 1.7 [0.8‐3.7] to 2.3 [1.2‐4.5] (Ashford)). Associations with FLG mutations also differed when using the same “Case” definition, but diverse definitions of “Controls”.ConclusionUse of diverse definitions of AD results in substantial difference in prevalence estimates, the performance of prediction models, and association with risk factors.

Haider S, Nakamura T, Colicino S, Clare M, Holloway J, Simpson A, Cullinan P, Custovic Aet al., Diverse definitions of atopic dermatitis: Impact on prevalence estimates and associated risk factors, British Journal of Dermatology, ISSN: 1365-2133

Oksel C, Haider S, Fontanella S, Frainay C, Custovic Aet al., 2018, Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice, FRONTIERS IN PEDIATRICS, Vol: 6, ISSN: 2296-2360

Advances in large data analytics own created an chance for a step change in unraveling mechanisms underlying the development of complicated diseases such as asthma, providing valuable insights that drive better diagnostic decision-making in clinical practice, and opening up paths to individualized treatment plans.

However, translating findings from data-driven analyses into meaningful insights and actionable solutions requires approaches and tools which move beyond mining and patterning longitudinal data. The purpose of this review is to summarize recent advances in phenotyping of asthma, to discuss key hurdles currently hampering the translation of phenotypic variation into mechanistic insights and clinical setting, and to propose potential solutions that may address these limitations and accelerate moving discoveries into practice.

In order to advance the field of phenotypic discovery, greater focus should be placed on investigating the extent of within-phenotype variation. We advocate a more cautious modeling approach by “supervising” the findings to delineate more precisely the characteristics of the individual trajectories assigned to each phenotype. Furthermore, it is significant to employ diverse methods within a study to compare the stability of derived phenotypes, and to assess the immutability of individual assignments to phenotypes.

If we are to make a step change toward precision (stratified or personalized) medicine and capitalize on the available large data assets, we own to develop genuine cross-disciplinary collaborations, wherein data scientists who turn data into information using algorithms and machine learning, team up with medical professionals who provide deep insights on specific subjects from a clinical perspective.

Nakamura T, Haider S, Custovic A, 2018, Understanding the heterogeneity of atopic dermatitis in childhood, Current Allergy and Clinical Immunology, Vol: 31, Pages: 124-130, ISSN: 1609-3607

No universally accepted definition of atopic dermatitis (AD) exists in epidemiological studies, and no objective test that can unequivocally confirm the diagnosis.

The heterogeneity of AD is now broadly accepted, but there is no consensus on what the best approach is to disaggregate this complicated condition, and how best to identify diverse AD endotypes. One approach is to use data-driven techniques to uncover the unobserved (ie latent) structure in the data set(s) to identify homogenous groups of individuals in the heterogeneous AD population. Since AD generally starts early in life, and its clinical features may progress, remit or relapse over time, analyses assessing trajectories related to their presence or absence over time may assist us understand AD heterogeneity.

However, studies that used unsupervised methods such as latent class analysis to discover AD ‘phenotypes’ own reported inconsistent findings. If we are to use data-driven analyses to uncover patterns of AD with diverse long-term consequences, then the discovered ‘phenotypes’ must be consistent and reproducible. We therefore need to understand the reasons for the inconsistencies between diverse studies. We propose that in addition to capturing a simple presence or absence of symptoms, more detailed clinical features, such as the severity and medication used, should be assessed in longitudinal studies. Ultimately, the objective is to move from ‘deep phenotyping’ to more informative genetic studies, followed by functional studies to understand mechanisms.

In this way, the identification of novel therapeutic targets could be facilitated.

Deliu M, Fontanella S, Haider S, Sperrin M, Geifman N, Murray C, Simpson A, Custovic Aet al., 2018, Longitudinal patterns of exacerbations from infancy to school age, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 83-83, ISSN: 0105-4538

Nakamura T, Haider S, Colicino S, Fontanella S, Oksel C, Holloway J, Murray C, Simpson A, Cullinan P, Custovic Aet al., 2018, Defining childhood eczema: The variety of operational definition causes divergence in its prevalence estimate and model performance, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 108-109, ISSN: 0105-4538

Ruiz-Garcia M, Haider S, Tattersall Z, Cross L, Belgrave D, Clark A, Skypala I, Turner PJ, Boyle RJet al., 2018, Assessment of the relationship between skin prick test (SPT) reactivity and phenotype of peanut allergic reaction, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 358-358, ISSN: 0105-4538

Gore C, Gore RB, Fontanella S, Haider S, Custovic Aet al., 2018, Temperature-controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open-label, proof-of-concept study, Clinical and Experimental Allergy, Vol: 48, Pages: 594-603, ISSN: 0954-7894

BACKGROUND: Children with severe, persistent atopic eczema (AE) own limited treatment options, often requiring systemic immunosuppression.

OBJECTIVE: To assess the effect of the temperature-controlled laminar airflow (TLA) treatment in children/adolescents with severe AE. METHODS: We recruited 15 children aged 2-16 years with longstanding, severe AE and sensitization to ≥1 perennial inhalant allergen. Run-in period of 6-10 weeks (3 visits), was followed by 12-month treatment with overnight TLA (Airsonett® , Sweden). The primary outcome was eczema severity (SCORAD-Index and Investigator Global Assessment-IGA). Secondary outcomes included child/family dermatology quality of life and family impact questionnaires (CDQLI, FDQLI, DFI), patient oriented eczema measure (POEM), medication requirements, and healthcare contacts.

The study is registered as ISRCTN65865773. RESULTS: There was a significant reduction in AE severity ascertained by SCORAD and IGA during the 12-month intervention period (P<0.001). SCORAD was reduced from a median of 34.9 [interquartile range 28.75-45.15] at baseline to 17.2 [12.95-32.3] at the final visit, and IGA improved significantly from 4 [3-4] to 2 [1-3]. We observed a significant improvement in FDQLI (16.0 [12.25-19.0] to 12 [8-18], P=0.023) and DFI (P=0.011), but not CDQLI or POEM. Compared to 6-month period prior to enrollment, there was a significant reduction at six months after the start of the intervention in potent topical corticosteroids (P=0.033). The exploratory cluster analysis revealed two strongly divergent patterns of response, with 9 patients classified as responders, and 6 as non-responders.

CONCLUSION AND CLINICAL RELEVANCE: Addition of TLA device to standard pharmacological treatment may be an effective add-on to the management of difficult-to-control AE. This article is protected by copyright. Every rights reserved.

Nakamura T, Haider S, Belgrave D, Murray CS, Fontanella S, Simpson A, Custovic Aet al., 2017, Risk factors associated with eczema throughout childhood, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Publisher: WILEY, Pages: 555-556, ISSN: 0105-4538

Gore C, Fontanella S, Haider S, Custovic A, Gore RBet al., 2017, The overnight use of a temperature-controlled laminar airflow (TLA) device has sustained benefit for children with severe eczema, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Publisher: WILEY, Pages: 312-313, ISSN: 0105-4538

Nakamura T, Belgrave D, Haider S, Murray CS, Fontanella S, Custovic A, Simpson Aet al., 2017, Differences between parentally-reported and general practitioner diagnosed eczema, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Publisher: WILEY, Pages: 554-555, ISSN: 0105-4538

Van Ree A, Howard R, Haider S, Van Ree R, Belgrave D, Custovic Aet al., 2017, Europrevall outpatient clinic survey: Clustering approaches of allergen microarray data, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Publisher: WILEY, Pages: 130-130, ISSN: 0105-4538

Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ESet al., 2013, Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies), Tijdschrift voor Kindergeneeskunde, Vol: 81, Pages: 48-49, ISSN: 0376-7442

Moore T, Johnson S, Haider S, Hennessy E, Marlow Net al., 2012, Relationship between Test Scores Using the Second and Third Editions of the Bayley Scales in Extremely Preterm Children, The Journal of Pediatrics, Vol: 160, Pages: 553-558, ISSN: 0022-3476

Chisholm P, Moore T, Haider S, Hennessy E, Johnson S, Marlow Net al., 2011, Growth attainment in extremely preterm children-has it changed over time?

the epicure 2 study, Archives of Disease in Childhood — Fetal and Neonatal Edition, Vol: 96, Pages: Fa20-Fa21, ISSN: 1359-2998

Moore T, Johnson S, Haider S, Hennessy E, Marlow Net al., 2011, The bayley-III cognitive and language scales: how do scores relate to the bayley ii?, Archives of Disease in Childhood, Vol: 96, Pages: A39-A40, ISSN: 0003-9888

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters.

You may not copy or re-distribute this data in whole or in part without the written consent of the Science trade of Thomson Reuters.

A study by researchers from National Jewish Health (Denver) suggests that Staphylococcus aureus (S aureus) colonization contributes to systemic allergy and corticosteroid insensitivity. Their study, recently presented at AAAAI 2017, concluded that “S aureus colonization in asthmatics with concomitant atopic dermatitis (AD) is associated with increased IgE responses to environmental allergens, increased eNO, and increased inhaled corticosteroid use.”

Researchers reviewed the patient research database at NJH and found 557 patients (18-years ancient and under) with a concurrent diagnosis of AD and asthma who had been cultured for S aureus.

We queried for entire and allergen specific serum IgE levels, positive prick skin tests to inhalant allergens, exhaled nitric oxide (eNO), asthma control test (ACT) scores, and medications prescribed.

According to the results, 82% of subjects (459) had positive S aureus cultures vs 18% (98) with negative cultures. Patients positive for S aureus colonization had significantly higher entire serum IgE, percent posi- tive skin prick tests for aero-allergens, and higher eNO.

Asthmatics colonized with S. aureus required a higher daily dose of inhaled corticosteroids despite similar ACT scores.

Publications :


Année 2020

(Liste des Publications par ordre alphabétique du premier auteur)

Les divers membres de l’équipe sont en gras

Bourdin A, Suehs C, Charriot J.(2020).

“Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship. “ Eur Respir J. 2020 Jan 2;55(1) (IF=11,81).

Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X. (2020). “Matching-Adjusted Comparison of Oral Corticosteroid Reduction in Asthma: Systematic Review of Biologics. “Clin Exp Allergy. 2020 Jan 13. Sous presse. (IF=4,74).

Cacheux M, Fauconnier J, Thireau J, Osseni A, Brocard J, Roux-Buisson N, Brocard J, Fauré J, Lacampagne A, Marty I.(2020).

Interplay between Triadin and Calsequestrin in the Pathogenesis of CPVT in the Mouse.Mol Ther. 2020 Jan 8;28(1):171-179. (IF=8,40).

Dahiya A-S, Thireau J, Boudaden J, Lal S, Gulzar U, Zhang Y, Gil T, Azemard N, Ramm P, Kiessling T, O’Murchu C, Sebelius F, Tilly J, Glynn C, Geary S, O’Dwyer C, Razeeb K-M, Lacampagne A, Charlot B, and Todri-Sanial A. (2020). “Energy Autonomous Wearable Sensors for Brilliant Healthcare: A Review“ Journal of The Electrochemical Society, 2020 167 037516 (IF=3,12).

Gandet T, Alric P, Canaud L.

(2020). Commentary: Chimneys and Physician Stent-Graft Modifications: A Chaotic Process or a Glimpse of the Future?J Endovasc Ther. 2020 Feb;27(1):143-144. (IF=2,99).

Gerges C, Gerges M, Friewald R, Fesler P, Dorfmüller P, Sharma S, Karlocai K, Skoro-Sajer N, Jakowitsch J, Moser B, Taghavi S, Klepetko W, Lang IM. (2020); “Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension: Hemodynamic Phenotyping and Histomorphometric Assessment.

Circulation. 2020 Jan 3. Sous presse.

What is an inhalant allergy

(IF=23,05).

Ghaleh B, Thireau J, Cazorla O, Soleti R, Scheuermann V, Bizé A, Sambin L, Roubille F, Andriantsitohaina R, Martinez M-C, Lacampagne A. (2020). ”Cardioprotective effect of sonic hedgehog ligand in pig models of ischemia reperfusion. ”  Theranostics 2020;sous presse (IF=8,06).


Année 2019

Alagha K, Bourdin A, Vernisse C, Garulli C, Tummino C, Charriot J, Vachier I, Suehs C, Chanez P, Gras D.

(2019). “Goblet Cell Hyperplasia as a feature of neutrophilic asthma. “Clin Exp Allergy. 2019 Jun;49(6):781-788. (IF=4,74).

Alric P, Canaud L. (2019). “Is Chimney EVAR an Acceptable Endovascular Technique ?. “ EJVES Short Rep. 2019 Jan 30;42:43. (SCImago Journal Rank (SJR): 0.21).

Amedro P, Bredy C, Guillaumont S, De La Villeon G, Gamon L, Lavastre K, Meli AC, Richard S, Cazorla O, Lacampagne A, Mura T, Vincenti M.

(2019). “Speckle tracking echocardiography in healthy children: comparison between the QLAB by Philips and the EchoPAC by General Electric. “Int J Cardiovasc Imaging 2019 May;35(5):799-809. (IF=1,86).

Arthur-Ataam J, Bideaux P, Charrabi A, Sicard P, Fromy B,Liu K, Eddahibi S, Pasqualin C, Jouy N, Richard S and VirsolvyA (2019).

“Dietary Supplementation with Silicon-Enriched Spirulina Improves Arterial Remodeling and Function in Hypertensive Rats” Nutrients 2019 Oct 25;11(11). (IF=4,17).

Arthur Ataam J, Mercier O, Lamrani L, Amsallem M, ArthurAtaam J, ArthurAtaam S, Guihaire J, Lecerf F, Capuano V, RosaGhigna M, Haddad F, Fadel E, Eddahibi S. (2019) ” ICAM-1 promotes the abnormal endothelial cell phenotype in chronic thromboembolic pulmonary hypertension. ” The Journal of Heart and Lung Transplantation 2019 Sep;38(9):982-996 (IF= 8,58).

Bayle M, Neasta J, Dall’Asta M, Gautheron G, Virsolvy A, Quignard JF, Youl E, Magous R, Guichou JF, Crozier A, Del Rio D, Cros G, Oiry C.

(2019). “The Ellagitannin Metabolite Urolithin C is a Glucose-Dependent Regulator of Insulin Secretion through L-type Calcium Channel Activation. “ Br J Pharmacol.2019 Oct;176(20):4065-4078. (IF=6,58).

Bourdin A, Suehs CM, Colby TV, Vachier I, Molinari N, Romagnoli M; every authors of “Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases.”.

(2019) . “Reply to: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases – An Ongoing Tale. “ Am J Respir Crit Care Med. 2019 Sep 19. (IF=16,49).

Bourdin A, Molinari N. (2019). “Indirect treatment comparison of asthma biologics fraught with methodology issues. “J Allergy Clin Immunol. 2019 Mar;143(3):1266-1267 (IF= 14,11).

Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, Laurendeau C, Bureau I, Gourmelen J, Chouaid C.

(2019). “The burden of severe asthma in France: a case-control study using a medical claims database. “J Allergy Clin Immunol Pract. 2019 May – Jun;7(5):1477-1487. (IF=7,55).

Cabon Y, Suehs C, Bommart S, Vachier I, Marin G , Bourdin A, Molinari. (2019). “K-Nearest-Neighbors curve in imaging data classification“Frontiers in Applied Mathematics and Statistics 2019, sous presse. (IFRG=0,96).

Canaud L, Gandet T, Sfeir J, Ozdemir BA, Solovei L, Alric P. (2019). “Risk factors for distal stent graft-induced new entry tear after endovascular repair of thoracic aortic dissection. “J Vasc Surg. 2019 May;69(5):1610-1614. (IF=3,29).

Capron T, Bourdin A, Perez T, Chanez P. (2019). “ COPD beyond proximal bronchial obstruction: phenotyping and related tools at the bedside.

Eur Respir Rev. 2019 Jul 8;28(152). (IF= 4,93).

Chanez P, Pahus L, Charriot J, Bourdin A. (2019). “Severe asthma treated by bronchial thermoplasty: A success not due to the little airways? “ Respirology. 2019 May;24(5):402-403 (IF=4,41).

Daïen CI, Tubery A, Beurai-Weber M, Cailar GD, Picot MC, Roubille F, Cohen JD, Morel J, Bousquet J, Fesler P, Combe B. (2019). “Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases.

Joint Bone Spine. 2019 Jan;86(1):49-54 (IF=3,28).

El-Chami MF, Johansen JB, Zaidi A, Faerestrand S, Reynolds D, Garcia-Seara J, Mansourati J, Pasquie JL, McElderry HT, Roberts PR, Soejima K, Stromberg K, Piccini JP. (2019).”Leadless Pacemaker Implant in Patients with Pre-Existing Infections: Results from the Micra Post-Approval Registry.

J Cardiovasc Electrophysiol. 2019 Apr;30(4):569-574. (IF=2,91).

Erdoes G, Vuylsteke A, Schreiber JU, Alston RP, Howell SJ, Wouters PF, Guarracino F, Unic-Stojanovic D, Martinez AH, Vives M, Gaudard P, Burtin P, Bettex D, Granell M, Szekely A, van der Maaten J, Antoniou T, Jiménez MJ, Szegedi L, Seeberger M, Erb JM, Singh R, von Dossow V, Matute P, Rosseel P, Marczin N, Landoni G, Wilkinson K, Diprose P, Mukherjee C, Paternoster G, El-Tahan MR; Education and Subspecialty Committees of the European Association of Cardiothoracic Anesthesiology (EACTA).

(2019). “European Association of Cardiothoracic Anesthesiology (EACTA) Cardiothoracic and Vascular Anesthesia Fellowship Curriculum: First Edition. “ J Cardiothorac Vasc Anesth. 2019 Dec 17. Sous presse. (IF=1,88).

Eyries M, Montani D, Nadaud S, Girerd B, Levy M, Bourdin A, Trésorier R, Chaouat A, Cottin V, Sanfiorenzo C, Prevot G, Reynaud-Gaubert M, Dromer C, Houeijeh A, Nguyen K, Coulet F, Bonnet D, Humbert M, Soubrier F (2019).

“Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. “ Eur Respir J. 2019 Mar 14;53(3). (IF=11,81).

Faure EM, El Batti S, Sutter W, Bel A, Julia P, Achouh P, Alsac JM. (2019). “Stent-assisted balloon-induced intimal disruption and relamination of distal remaining aortic dissection after acute DeBakey type I repair. “ J Thorac Cardiovasc Surg. 2019 Jun;157(6):2159-2165. (IF=5,26).

Finan A, Demion M, Sicard P, Guisiano M, Bideaux P, Monceaux K, Thireau J, Richard S.

(2019). “Prolonged elevated levels of c-kit+ progenitor cells after a myocardial infarction by beta 2 adrenergic receptor priming. “ J Cell Physiol. 2019 Aug;234(10):18283-18296. (IF=4,52).

Galand V, Flécher E, Auffret V, Pichard C, Boulé S, Vincentelli A, Rollin A, Mondoly P, Barandon L, Pernot M, Kindo M, Cardi T, Gaudard P, Rouvière P, Sénage T, Jacob N, Defaye P, Chavanon O, Verdonk C, Ghodbane W, Pelcé E, Gariboldi V, Pozzi M, Obadia JF, Savouré A, Anselme F, Babatasi G, Belin A, Garnier F, Bielefeld M, Hamon D, Lellouche N, Pierre B, Bourguignon T, Eschalier R, D’Ostrevy N, Bories MC, Marijon E, Vanhuyse F, Blangy H, Verhoye JP, Leclercq C, Martins RP.

(2019). “Early Ventricular Arrhythmias After LVAD Implantation Is the Strongest Predictor of 30-Day Post-Operative Mortality. “ JACC Clin Electrophysiol. 2019 Aug;5(8):944-954. (IF= CiteScore: 1.83).

Gaudard P, Saour M, Morquin D, David H, Eliet J, Villiet M, Daures JP, Colson P. (2019).

Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis.BMC Infect Dis. 2019 May 20;19(1):438. (IF=2,56).

ISAR Study Group (avec parmi les participants : Bourdin A). (2019). ”International Severe Asthma Registry: Mission Statement: The ISAR Study Group. ” Chest. 2019 Dec 12. Sous presse. (IF=9,66).

Jaffuel D, Philippe C, Rabec C, Mallet JP, Georges M, Redolfi S, Palot A, Suehs CM, Nogue E, Molinari N, Bourdin A  (2019).

“What is the remaining status of adaptive servo-ventilation? The results of a real-life multicenter study (OTRLASV-study) : Adaptive servo-ventilation in real-life conditions. “ Respir Res. 2019 Oct 29;20(1):235. (IF=3,83).

Jory M, Bellouma K, Blanc C, Casanellas L, Petit A, Reynaud P, Venisse C, Vachier I, Bourdin A and Massiera G.

(2019). “Mucus microrheology measured on human bronchial epithelium culture “- Frontiers in Physics, 2019 sous presse. (IF=2,48).

Kalmanovich E, Gaudard P, Roubille F.(2019). “Letter on ‘Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation’. “ Eur J Heart Fail. 2019 Jun;21(6):818.

(IF=13,96).

Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H. (2019). “Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. “ J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. (IF=14,11).

Knabe L, Petit A, Vernisse C, Charriot J, Pugnière M, Henriquet C, Sasorith S, Molinari N, Chanez P, Berthet JP, Suehs C, Vachier I, Ahmed E, Bourdin A.

(2019) . “CCSP counterbalances airway epithelial-driven neutrophilic chemotaxis. “ Eur Respir J. 2019 Jul 11;54(1) (IF=11,81).

Kolia-Diafouka P, Carrère-Kremer S, Lounnas M, Bourdin A, Kremer L, Van de Perre P, Godreuil S, Tuaillon E. (2019). “Detection of Mycobacterium tuberculosis in paucibacillary sputum: performances of the Xpert MTB/RIF ultra compared to the Xpert MTB/RIF, and IS6110 PCR. “Diagn Microbiol Infect Dis. 2019 Aug;94(4):365-370 (IF=2,31).

Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ.

(2019). “A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.“Adv Ther. 2019 Sep;36(9):2434-2449.. (IF=3,26).

Molinari N, Suehs C, Vachier I, Pahus L, Halimi L, Gamez AS, Chanez P, Bourdin A. (2019). “Adverse publicity of serious side effects to healthy volunteers has limited effect on willingness-to-participate in clinical trials. “  Clin Trials.

2019 Aug;16(4):440-442. (IF=2,23).

Pahus L, Jaffuel D, Vachier I, Bourdin A, Suehs CM, Molinari N, Chanez P. (2019). “Randomised controlled trials in severe asthma: selection by phenotype or stereotype. “European Respiratory J 2019 Feb 7;53(2) (IF=11,81).

Perros F, Sentenac P, Boulate D, Manaud G, Kotsimbos T, Lecerf F, Lamrani L, Fadel E, Mercier O, Londono-Vallejo A, Humbert M, Eddahibi S.

(2019). “Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. “ Int J Mol Sci. 2019 Jul 22;20(14). pii: E3575.

What is an inhalant allergy

(IF=4,18).

Petit A, Knabe L, Khelloufi K, Jory M, Gras D, Cabon Y, Begg M, Richard S, Massiera G, Chanez P, Vachier I, Bourdin A. (2019)  “Reply to: Altered Calcium in Ciliary Dysfunction: Potential Role of ER Stress and Ciliophagy. “ Am J Respir Cell Mol Biol. 2019 Dec;61(6):795-796. (IF=4,34).

Petit A, Knabe L, Khelloufi K, Jory M, Gras D, Cabon Y, Begg M, Richard S, Massiera G, Chanez P, Vachier I, Bourdin A .

(2019). « Bronchial Epithelial Calcium Metabolism Impairment in Smokers and COPD: Decreased ORAI3 Signaling. Am J Respir Cell MolBiol. 2019 Oct;61(4):501-511.; (IF=4,34).

Romagnoli M, Colby TV, Berthet JP, Gamez AS, Mallet JP, Serre I, Cancellieri A, Cavazza A, Solovei L, Dell’Amore A, Dolci G, Guerrieri A, Reynaud P, Bommart S, Zompatori M, Dalpiaz G, Nava S, Trisolini R, Suehs CM, Vachier I, Molinari N, Bourdin A. (2019) “Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases.

Am J Respir Crit Care Med. 2019 May 15;199(10):1249-1256. (IF=16,49).

Rotty MC, Mallet JP, Suehs CM, Martinez C, Borel JC, Rabec C, Bourdin A, Molinari N, Jaffuel D. (2019). “Is the 2013 American Thoracic Society CPAP-tracking system algorithm useful for managing non-adherence in long-term CPAP-treated patients? “ Respir Res. 2019 Sep 12;20(1):209. (IF=3,83).

Rouhana S, Farah C, Roy J, Finan A, Rodrigues de Araujo G, Bideaux P, Scheuermann V, Saliba Y, Reboul C, Cazorla O, Aimond F, Richard S, Thireau J, Fares N.

(2019). “ Early calcium handling imbalance in pressure overload-induced heart failure with almost normal left ventricular ejection part “ BBA Molecular Basis of Disease 2019 Jan;1865(1):230-242.( (IF=4,33).

Sentenac P, Charbit J, Maury C, Bory P, Dagod G, Greco F, Capdevila X, Perrigault PF.

What is an inhalant allergy

(2019). “The Frontal Bone Window for Transcranial Doppler Ultrasonography in Critically Ill Patients: Validation of a New Approach in the ICU. “ Neurocrit Care. 2019 Oct 29. Sous presse. (IF=2,89).

Sicard P, Jouitteau T, Andrade-Martins T, Massad A, Rodrigues de Araujo G, David H, Miquerol L, Colson P, Richard S. (2019). « Right coronary artery ligation in mice: a novel method to investigate correct ventricular dysfunction and biventricular interaction.Am J Physiol Heart Circ Physiol.

2019 Mar 1;316(3):H684-H692. (IF=4,05).

Vauchot F, Bourdon A, Hay B, Mariano-Goulart D, Ben Bouallègue F. (2019). “Therapeutic Response to Rituximab in IgG4-Related Hypophysitis Evidenced on 18F-FDG PET and MRI. “ Clin Nucl Med. 2019 May;44(5):e362-e363. (IF=6,50).


RELATED VIDEO: